T1	Participants 376 473	Fifty-nine HIV-infected women were enrolled in a randomized double-blind placebo-controlled study
T2	Participants 716 753	Thirty-nine (66%) of the participants
T3	Participants 855 867	participants
T4	Participants 895 906	Fewer women
T5	Participants 1004 1022	Eleven (19%) women
T6	Participants 1145 1162	placebo gel group
T7	Participants 1548 1561	male partners
